E-LIB Suche - Ergebnisse für: Dobo, Krista L.

1

Mechanisms of Nitrosamine Mutagenicity and Their Relationsh..:

Snodin, David J. ; Trejo-Martin, Alejandra ; Ponting, David J....
Chemical Research in Toxicology. 37 (2024) 2 - p. 181-198 , 2024

Link: https://doi.org/10.1021/..

2

A Case to Support the Continued Use of Rifampin in Clinical..:

Bercu, Joel P. ; Ponting, David J. ; Ripp, Sharon L....
Clinical Pharmacology & Therapeutics. 116 (2024) 1 - p. 34-37 , 2024

Link: https://doi.org/10.1002/..

3

N-nitrosamine safety assessments - Current challenges:

Dobo, Krista
Drug Metabolism and Pharmacokinetics. 55 (2024) - p. 100580 , 2024

Link: https://doi.org/10.1016/..

4

Practical and Science-Based Strategy for Establishing Accep..:

Dobo, Krista L. ; Kenyon, Michelle O. ; Dirat, Olivier...
Chemical Research in Toxicology. 35 (2022) 3 - p. 475-489 , 2022

Link: https://doi.org/10.1021/..

5

Strategies for Assessing Acceptable Intakes for Novel N-Nit..:

Ponting, David J. ; Dobo, Krista L. ; Kenyon, Michelle O..
Journal of Medicinal Chemistry. 65 (2022) 23 - p. 15584-15607 , 2022

Link: https://doi.org/10.1021/..

6

Permitted daily exposure limits for noteworthy N‐nitrosamin..:

Johnson, George E. ; Dobo, Krista ; Gollapudi, Bhaskar...
Environmental and Molecular Mutagenesis. 62 (2021) 5 - p. 293-305 , 2021

Link: https://doi.org/10.1002/..

7

Deriving Compound-Specific Exposure Limits for Chemicals Us..:

Drewe, William C. ; Dobo, Krista L. ; Sobol, Zhanna...
International Journal of Toxicology. 40 (2021) 3 - p. 285-298 , 2021

Link: https://doi.org/10.1177/..

8

Management of pharmaceutical ICH M7 (Q)SAR predictions – Th..:

Hasselgren, Catrin ; Bercu, Joel ; Cayley, Alex...
Regulatory Toxicology and Pharmacology. 118 (2020) - p. 104807 , 2020

Link: https://doi.org/10.1016/..

9

Genetic toxicology in silico protocol:

Hasselgren, Catrin ; Ahlberg, Ernst ; Akahori, Yumi...
Regulatory Toxicology and Pharmacology. 107 (2019) - p. 104403 , 2019

Link: https://doi.org/10.1016/..

10

Principles and procedures for handling out-of-domain and in..:

Amberg, Alexander ; Andaya, Roxanne V. ; Anger, Lennart T....
Regulatory Toxicology and Pharmacology. 102 (2019) - p. 53-64 , 2019

Link: https://doi.org/10.1016/..

11

2‐Hydroxypyridine N‐Oxide is not genotoxic in vivo:

Dobo, Krista L. ; Coffing, Stephanie ; Gunther, William C..
Environmental and Molecular Mutagenesis. 60 (2019) 7 - p. 588-593 , 2019

Link: https://doi.org/10.1002/..

12

In Vivo Mutagenicity Testing of Arylboronic Acids and Ester:

Masuda‐Herrera, Melisa J. ; Dobo, Krista L. ; Kenyon, Michelle O....
Environmental and Molecular Mutagenesis. 60 (2019) 9 - p. 766-777 , 2019

Link: https://doi.org/10.1002/..

13

A pharma-wide approach to address the genotoxicity predicti..:

Patel, Mukesh ; Kranz, Michael ; Munoz-Muriedas, Jordi...
Computational Toxicology. 7 (2018) - p. 27-35 , 2018

Link: https://doi.org/10.1016/..

14

2‐Hydroxypyridine‐N‐oxide (HOPO): Equivocal in the ames ass..:

Dobo, Krista L. ; Cheung, Jennifer R. ; Gunther, William C..
Environmental and Molecular Mutagenesis. 59 (2018) 4 - p. 312-321 , 2018

Link: https://doi.org/10.1002/..

15

In silico toxicology protocols:

Myatt, Glenn J. ; Ahlberg, Ernst ; Akahori, Yumi...
Regulatory Toxicology and Pharmacology. 96 (2018) - p. 1-17 , 2018

Link: https://doi.org/10.1016/..